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Abstract atrial fibrillation (AF) is associated with a significant burden of morbidity and increased risk of mortality. Antiarrhythmic
drug therapy remains a cornerstone to restore and maintain sinus rhythm for patients with paroxysmal and persistent AF
based on current guidelines. However, conventional drugs have limited efficacy, present problematic risks of proarrhythmia and
cause significant noncardiac organ toxicity. Thus, inadequacies in current therapies for atrial fibrillation have made new drug
development crucial. New antiarrhythmic drugs and new anticoagulant agents have changed the current management of AF. This
paper summarizes the available evidence regarding the efficacy of medications used for acute management of AF, rhythm and
ventricular rate control, and stroke prevention in patients with atrial fibrillation and focuses on the current pharmacological
agents.
1. Introduction
Atrial fibrillation (AF) is the most common cardiac rhythm
disturbance seen in clinical practice accounting for approx-
imately one-third of hospitalizations [1]. AF may occur
isolated or in association with structural heart disease, con-
tributing substantially to cardiac morbidity and mortality.
The estimated prevalence of AF is 0.4–1% in the general
population, increasing with age [2, 3], and it is associated
with an higher long-term risk of stroke, heart failure, and all-
cause mortality, especially in women [4, 5].
Management of patients with AF requires knowledge of
its pattern of presentation [6] (first diagnosed, paroxysmal,
persistent, long-standing, and permanent AF, Figure 1),
underlying conditions, and decisions about restoration and
maintenance of sinus rhythm, control of the ventricular rate,
and antithrombotic therapy.
Antiarrhythmic drug therapy is the first-line treatment
for patients with paroxysmal and persistent AF based on
current guidelines [6, 7]. Prevention of AF-related complica-
tions relies on antithrombotic therapy, control of ventricular
rate, and adequate therapy of concomitant cardiac diseases.
However, available drug therapy has major limitations,
including incomplete effectiveness, cardiac and extracardiac
toxicity and risk of life-threatening proarrhythmic complica-
tions (antiarrhythmic agents), and bleeding (anticoagulants)
[8–11].
Thus, there is a continuing need for new drugs, device,
and ablative approaches to rhythm restoration, and simpler
and safer stroke prevention regimens are needed for AF
patients on life-long anticoagulation [12].
This paper summarizes the available evidence regarding
the efficacy of medications used for ventricular rate control,
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Figure 1: Classification of atrial fibrillation.
stroke prevention, acute conversion, and maintenance of
sinus rhythm in patients with atrial fibrillation.
2. Acute Management
The acute management of patients with AF is driven by
acute protection against thromboembolic events and acute
improvement of cardiac function. The severity of AF-related
symptoms should drive the decision for acute restoration
of sinus rhythm or acute management of the ventricular
rate. In stable patients with a rapid ventricular response,
the acute control of ventricular rate can be achieved by oral
administration of β-blockers or nondihydropyridine calcium
channel antagonists. In contrast, in severely compromised
patients, i.v. verapamil or metoprolol may be used [6].
In patients who remain symptomatic despite adequate
rate control, or in patients in whom rhythm control therapy
is pursued, pharmacological cardioversion of AF may be
initiated by a bolus administration of an antiarrhythmic drug
(Table 1) [6].
In the acute setting, flecainide has an established effect on
restoring sinus rhythm in patients with AF of short duration
(<24 hours) [6, 13]. Patients undergoing flecainide treat-
ment, should be checked for contraindications including
structural heart disease, second- or third-degree AV block,
left-bundle branch block, right-bundle branch block (when
associated with left hemiblock), asymptomatic nonsustained
ventricular tachycardia, cardiogenic shock, reduced cardiac
output (LVEF < 35%), post-MI, and significant renal or
hepatic impairment [6, 13]. Flecainide is also a safe and
effective agent for termination of AF in patients with Wolff-
Parkinson-White (WPW) syndrome [14].
Propafenone is indicated to convert recent onset AF to
sinus rhythm in patients without abnormal LV function and
ischemia, but it has a limited efficacy to convert atrial flutter
[15, 16].
In patients with underlying heart disease, amiodarone
can be employed as it blocks Na+, Ca2+, and K+ channels
[17] and inhibits the consequences of α adrenoceptor and
β-adrenoceptor stimulation [18]. Nonetheless, it does not
achieve cardioversion in the short and medium terms [6].
Ibutilide is a useful agent for the pharmacological cardiover-
sion of recent-onset atrial fibrillation but is more effective
in terminating atrial flutter. It prolongs the myocardial
action potential duration and effective refractory periods
in both the atria and the ventricles. The mean times to
conversion were ≤30minutes [19]. Its cellular electrophysi-
ologic mechanism increases the slow inward plateau sodium
current and inhibits the outward repolarizing potassium
current. Adverse events associated with ibutilide are pre-
dominantly proarrhythmic effects [20, 21]. The drug has
minimal haemodynamic effects and is associated with few
non-cardiovascular adverse events [22–26].
Vernakalant is a relative atrialselective antiarrhythmic
agent [27] recently recommended for approval by the Euro-
pean Medicines Agency for rapid cardioversion of recent-
onset AF to sinus rhythm in adults (≤7 days for non-surgical
patients; ≤3 days for surgical patients) [28, 29]. Atrial
selectivity of vernakalant is achieved by targeting atrial-
specific channels: the Kv1.5 channel which carries K+ current
(IKur) and the Kir3.1/3.4 channel which carries muscarinic
K+ current (IKAch). Vernakalant can also work to block Ito,
late Ina, with minor blockade of IKr currents [30, 31].
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Table 1: Acute rhythm management.
Drug Dose Followup dose Risks
Amiodarone 5mg/kg i.v. over 1 h 50mg/h
Phlebitis, hypotension. Will slow the ventricular rate.
Delayed AF conversion to sinus rhythm.
Flecainide
2mg/kg i.v. over 10min,
or 200–300mg p.o.
N/A
May prolong QRS duration and the QTinterval, and may
increase the ventricular rate due to conversion to atrial
flutter and 1 : 1 conduction to the ventricles.
Ibutilide 1mg i.v. over 10min
1mg i.v. over 10min
after waiting for 10min
Can cause prolongation of the QT interval and torsades de
pointes; watch for abnormal T-U waves or QT
prolongation. Will slow the ventricular rate.
Propafenone
2mg/kg i.v. over 10min,
or 450–600mg p.o
N/A
May prolong QRS duration, will slightly slow the
ventricular rate, but may increase the ventricular rate due
to conversion to atrial flutter and 1: 1 conduction to the
ventricles.
Vernakalant 3mg/kg i.v. over 10min
Second infusion of
2mg/kg i.v. over 10min
after 15min rest
Recently approved by the European Medicines Agency.
A direct comparison with amiodarone in the AVRO trial
[32] showed that vernakalant was more effective than
amiodarone for the rapid conversion of AF to sinus rhythm
(51.7% versus 5.7% at 90min after the start of treatment,
P < .0001). Intravenous vernakalant is generally given at
an initial dose of 3mg/kg, and then an additional 2mg/kg
if atrial fibrillation conversion fails after 15min. The elimi-
nation half-life is about 2 h. Vernakalant is contraindicated
in patients with systolic blood pressure <100mm Hg, severe
aortic stenosis, heart failure (class NYHA III and IV), acute
coronary syndrome (ACS) within the previous 30 days, or
QT interval prolongation [30–33]. Furthermore, before its
use, the patients should be adequately hydrated. In addition,
ECG and hemodynamic monitoring should be used, and
the infusion can be followed by direct current cardioversion
(DCC) if necessary [30–33]. The drug is not contraindicated
in patients with stable coronary artery disease, hypertensive
heart disease, or mild heart failure. The clinical positioning
of this drug has not been determined yet, but it is likely to
be used for acute termination of recent-onset AF in patients
with lone AF or AF associated with hypertension, coronary
artery disease, or mild- to moderate- (NYHA class I-II) heart
failure [34].
The ACC/AHA/ESC guidelines identify dofetilide, ibu-
tilide, and amiodarone as agents with efficacy for pharmaco-
logic cardioversion of atrial fibrillation >7 days and disopyra-
mide, flecainide, procainamide, propafenone, and quinidine
as less effective or incompletely studied [13]. The so-
called “pill-in-the-pocket” approach may be used in selected,
highly symptomatic patients with infrequent (once/month
to once/year) recurrence of atrial fibrillation. According to
a medium-size trial 1, oral propafenone (450–600mg) of
flecainide (200–300mg) can be administered by patients
safely (1/569 episodes resulting in atrial flutter with rapid
conduction) and effectively (94%, 534/569 episodes) out
of hospital. In order to implement the pill-in-the-pocket
technique, patients should be screened for indications and
contraindications, and the efficacy and safety of oral treat-
ment should be tested in hospital. Finally, patients should be
instructed to take flecainide or propafenone when symptoms
of AF occur [35].
3. Long-Term Management
The restoration and maintenance of sinus rhythm has been
shown to be associated with reduced atrial remodeling,
improved left ventricular function, reduced symptoms,
greater exercise tolerance, increased ability to perform
activities of daily living, and improved quality of life [36].
However, rates of attainment and maintenance of sinus
rhythm have been suboptimal in comparative studies such
as atrial fibrillation followup investigation of rhythm man-
agement (AFFIRM) [37], Polish how to treat chronic atrial
fibrillation (HOT CAFE`) [38], pharmacological intervention
in atrial fibrillation (PIAF) [39], rate control versus electrical
cardioversion (RACE) [40], strategies of treatment in atrial
fibrillation (STAF) [41] and atrial fibrillation and congestive
heart failure (AF-CHF) [42]. Furthermore studies failed
to demonstrate a survival advantage with either approach
by intention-to-treat analysis—both in patients with and
without heart failure (HF) [36, 43].This is probably because
the antiarrhythmic therapies studied had limited efficacy,
poor tolerability, and the potential to trigger new arrhyth-
mias. Moreover, several of the antiarrhythmic drugs used for
rhythm control in these studies were associated with a sig-
nificant increase in noncardiovascular deaths [36]. However,
the results do not support the hypothesis that rate control is
preferable as first-line therapy for AF with respect to survival
and do not disprove the hypothesis that maintenance of sinus
rhythm is preferable to the continuation of AF, particularly if
rate control fails to restore adequate quality of life (QOL) or
whether selective approaches are employed. Many posthoc
analyses and substudies have assessed QOL, functional sta-
tus, and exercise tolerance, with the majority demonstrating
important benefits associated with achievement of rhythm
control. Moreover, some subanalyses and additional trials
have suggested that sinus rhythm can be associated with
longer survival, including in patients with HF [43].
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Current guidelines indicate paroxysmal AF is more often
managed with a rhythm control strategy, especially if it is
symptomatic and there is little or no associated underlying
heart disease.
Permanent AF is managed by rate control unless it is
deemed possible to restore sinus rhythm when the AF
category is redesignated as “long-standing persistent”. Rate
control is needed for most patients with AF unless the heart
rate during AF is naturally slow. Rhythm control may be
added to rate control if the patient is symptomatic despite
adequate rate control, or if a rhythm control strategy is
selected because of factors such as the degree of symptoms,
younger age, or higher activity levels [6].
4. Maintenance of Normal Sinus Rhythm
A number of agents are effective for the maintenance of
normal sinus rhythm in patients with atrial fibrillation.
According to current guidelines, amiodarone, dronedarone,
flecainide, propafenone, sotalol, and disopyramide are rec-
ommended for rhythm control depending on the underlying
heart disease (Figure 2) [6].
The new ESC 2010 AF guidelines mention for the
first time dronedarone as a recommended treatment in
patients with AF [6]. Dronedarone is a multichannel blocker
which inhibits sodium, potassium, and calcium channels
with a noncompetitive antiadrenergic activity. Its short half-
life (of approximately 24 h) reduces the accumulation in
tissues and the low lipophilicity as well as elimination of
iodine moieties, which reduces its toxicity. Dronedarone
prolongs the action potential duration and reduces heart
rate, with low proarrhythmic effect [1, 44]. Maximum
dronedarone plasma concentrations are reached within 1–
4 h [45]. Steady-state concentrations are achieved within 7
days of 400mg twice daily [46]. Dronedarone is extensively
biotransformed by cytochrome P450 (CYP3A4) enzymes,
with little excretion of unchanged drug in bile and urine.
The elimination half-life (about 24 h) is much shorter than
that for amiodarone, which is very slow (up to many
weeks) because of delayed removal from adipose tissue
stores. Potent CYP3A4 inhibitors (e.g., ketoconazole or ery-
thromycin) can raise dronedarone plasma concentrations.
Dronedarone increases serum digoxin levels by inhibition
of P-glycoprotein intestinal and renal excretion and can
raise serum creatinine concentrations by inhibition of renal
organic-cation transport [47].
In patients with adrenergic AF and no or minimal
structural heart disease, dronedarone is recommended if β-
blocking agents (including sotalol) are not effective [48]. In
patients with left ventricular hypertrophy, coronary artery
disease, and stable NewYorkHeart Association (NYHA) class
I/II, dronedarone is the antiarrhythmic drug of choice. How-
ever, dronedarone should not be used in AF patients with
NYHA class III/IV or in unstable patients with NYHA class
II. In these patients, β-blocking agents are recommended as
first-line therapy [6, 48].
According to 2011 ACCF/AHA/HRS focused update on
the management of patients with atrial fibrillation [7],
dronedarone is reasonable to decrease the need for hospital-
ization for cardiovascular events in patients with paroxysmal
AF or after conversion of persistent AF. Dronedarone can
be initiated during outpatient therapy (Class IIa, Level of
Evidence B) [49]. Dronedarone should not be administered
to patients with class IV heart failure or patients who have
had an episode of decompensated heart failure in the past
4 weeks, especially if they have depressed left ventricular
function (left ventricular ejection fraction ≤35%, Class III–
Harm, Level of Evidence B) [50].
The EURIDIS (european trial in atrial fibrillation or
flutter patients receiving dronedarone for themaintenance of
sinus rhythm) and ADONIS (American-Australian-African
Trial With Dronedarone in Atrial Fibrillation or Flutter
Patients for the Maintenance of Sinus Rhythm) trials [51, 52]
found that dronedarone prolongs the time to recurrence
AF. Posthoc analyses of pooled EURIDIS and ADONIS data
showed that dronedarone greatly decreased the combined
endpoint of admission or death. The efficacy of dronedarone
for rate control in patients with permanent atrial fibrillation
was tested in the ERATO trial [53].
Possessing both rate- and rhythm-control properties,
dronedarone has proved safe and effective in preventing AF
recurrence in patients with persistent AF in the DAFNE
(dronedarone atrial fibrillation study after electrical car-
dioversion) trial, the first prospective randomized trial to
evaluate its efficacy and safety [54].
In the DIONYSOS [55] (efficacy & safety of dronedarone
versus amiodarone for the maintenance of sinus rhythm in
patients with persistent atrial fibrillation), a short-term,
randomized, double-blind, parallel-group study, in patients
with persistent atrial fibrillation, dronedarone was less effi-
cacious but also less toxic than amiodarone. Recurrence of
AF during followup at 12 months and study drug discontin-
uation occurred in 75% and 59% of patients treated with
dronedarone and amiodarone, respectively (hazard ratio
(HR) 1.59; 95% CI 1.28–1.98; P < .0001). AF recurrence
was more common in the dronedarone arm compared
with amiodarone (36.5% versus 24.3%). Premature drug
discontinuation tended to be less frequent with dronedarone
(10.4% versus 13.3%). The safety profile of dronedarone
is advantageous in patients without structural heart dis-
ease and in stable patients with heart disease. Specifically,
dronedarone appears to have a low potential for proarrhyth-
mia. Fewer thyroid, neurologic, dermatologic, and ocular
events occurred in the dronedarone group. These data sug-
gest higher tolerability but less efficacy for dronedarone than
for amiodarone [52, 55].
The ANDROMEDA (antiarrhythmic trial with drone-
darone in moderate- to- severe CHF evaluating morbidity
decrease) trial in patients in sinus rhythm and systolic
left ventricular dysfunction was prematurely discontinued
because of increased mortality with dronedarone. The deaths
in the dronedarone group were due predominantly to heart
failure, and there was no evidence of proarrhythmia or an
increased incidence of sudden death. Six months after dis-
continuationmortality rates were similar, but dronedarone is
nevertheless contraindicated in class III and IV heart failure
[56].
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Figure 2: ACC/AHA/ESC algorithm for antiarrhythmic maintenance drug therapy. ∗The dosage must be patient-tailored.
The ATHENA study (A placebo-controlled, double-
blind, parallel arm trial to assess the efficacy of dronedarone
400mg b.i.d. for the prevention of cardiovascular hospital-
ization or death from any cause in patients with atrial fibrilla-
tion/atrial flutter) randomized 462 patients with paroxysmal
or persistent AF or flutter and cardiovascular risk factors to
treatment with dronedarone or placebo, assessing a substan-
tially reduction of primary endpoint (all-cause mortality and
cardiovascular admissions) 31.9% versus 39.4% on placebo,
HR 0.76 (0.69–0.84) driven by reduction in cardiovascular
admission events: 29.3% versus 36.9 on placebo (HR 0.74
(0.67–0.82), but nonsignificant difference in all cause mor-
tality.
Dronedarone improved the composite endpoint of car-
diovascular hospitalizations and all-cause mortality in a
carefully selected, high-risk, nonpermanent AF population,
in addition to its recognized reduction in AF [57]. The rate
of cardiovascular mortality was lower in the dronedarone
group (2.7% versus 3.9%; HR 0.71; 95% CI 0.51–0.98). The
median time to first artial fibrillation or recurrence of atrial
flutter was increased by dronedarone, and the likelihood
of permanent atrial fibrillation or atrial flutter was greatly
reduced [58]. The ATHENA trial excluded patients with
decompensated heart failure within the previous 4weeks, or
with NYHA class IV heart failure. There was no evidence
of an adverse effect of dronedarone in patient subgroups
with a history of congestive heart failure or LV ejection
fraction ≤35% [57]. The major adverse cardiac effects of
dronedarone are bradycardia and QT prolongation. Torsades
de pointes have been reported [57]. Like amiodarone,
dronedarone inhibits renal tubular secretion of creatinine,
which can increase plasma creatinine levels. However, there
is no reduction in glomerular filtration rate. Dronedarone
increases digoxin levels 1.7- to 2.5-fold.31 Dronedarone is
predominantly metabolized by the liver (CYP3A4) with a
half-life of approximately 19 hours. It should not be admin-
istered with strong inhibitors of CYP3A4 (e.g., ketoconazole
and macrolide antibiotics), because these may potentiate the
effects of dronedarone. It can be administered with verapamil
or diltiazem, which aremoderate CYP3A4 inhibitors, but low
doses of these agents should be used initially and titrated
according to response and tolerance [59]. Dronedarone does
not alter the international normalization ratio when used
with warfarin. The recommended oral dose of dronedarone
is 400mg twice a day with meals. An intravenous form is not
available.
In maintaining sinus rhythm, amiodarone is more
effective than others agent and has restricted proarrhythmic
potential, but, because of its very long half-life and profile
toxicity with severe extracardiac side effects [60], should
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be generally use when other therapies have failed or are
contraindicated. In patients with severe heart failure, NYHA
class III and IV or recently unstable NYHA class II (decom-
pensation within the prior month), amiodarone should be
the drug of choice [6].
Nonetheless, although amiodarone is the widely consid-
ered for maintenance of sinus rhythm in atrial fibrillation
management, it lacks FDA approval for this indication.
5. Inhibitors of the
Renin-Angiotensin-Aldosterone System
Atrial angiotensin II concentrations increase in atrial fibril-
lation [61] and stimulation of its receptors activates nicoti-
namide adenine dinucleotide-phosphate (NADPH) oxidase
to produce oxidative stress or inflammation [62]. Several
studies [63–65] suggest benefit of angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II type 1 (AT1)-
blockers in prevention of atrial fibrillation, especially in
patients with left ventricular hypertrophy or dysfunction.
particularly, patients treated with amiodarone plus irbesar-
tan showed a lower rate of recurrence of atrial fibrillation
than did patients treated with amiodarone alone [65, 66].
However, the large placebo-controlled GISSI-AF trial
showed that valsartan did not reduce recurrence rates of
atrial fibrillation, raising questions about the value of
AT1 blockers in secondary prevention [67]. Furthermore,
preliminary results of the ACTIVE I trial, including 9016
atrial fibrillation patients during a follow-up of 4.1 years,
showed that irbesartan did not prevent cardiovascular events
and had no effect on atrial fibrillation burden [68].
Further prospective studies are needed to establish the
potential therapeutic value of ACE inhibitors and AT1
blockers in prevention of atrial fibrillation and to define the
populations of patients that benefit.
Aldosterone exerts many cardiac effects. In small animals,
it causes atrial fibrosis, and spironolactone prevents fibrosis
[69]. Selective aldosterone receptor blockade also suppresses
atrial fibrillation in animal models of heart failure [70].
Plasma aldosterone concentrations increase in patients with
atrial fibrillation [71], and atrial expression of the aldos-
terone receptor is higher in these patients than in those
without the disorder [72]. Furthermore, patients with pri-
mary hyperaldosteronism have a 12-fold greater risk of atrial
fibrillation than do controls matched for blood pressure
[73]. Hence, blockade of aldosterone receptors could be a
therapeutic option for patients with atrial fibrillation, but
data from trials are not available.
6. Anti-Inflammatory Agents
Glucocorticoids have powerful anti-inflammatory properties
and have efficacy against atrial fibrillation in animal [74]
and clinical [75] studies although their potential toxicity
restricts their value in this disorder. Both statins and omega-
3 fatty acids have anti-inflammatory and antioxidant actions.
Statins are effective against several substrates that maintain
atrial fibrillation [76, 77]. Statins are of benefit in prevention
of atrial fibrillation, especially for postoperative AF [78].
Epidemiological data about the effects of omega-3 fatty-acids
on occurrence of AF are conflicting [79]. Animal studies [80]
show model dependent atrial-fibrillation-preventing effects,
suggesting that omega-3 fatty acids prevent atrial fibrillation,
especially in patients at risk of fibrotic structural remodeling.
Peroxisome proliferator-activated receptor γ activators, such
as pioglitazone, might suppress adverse cardiac remodeling
and susceptibility to atrial fibrillation [81] but can also
cause salt retention and might predispose to development of
congestive heart failure.
7. Pharmacological Rate Control
Commonly, beta-blockers, nondihydropyridine calcium
channel blockers, and digitalis are appropriate for most
patients with persistent or permanent atrial fibrillation
for whom control of ventricular rate is desired. For most
patients, a target heart rate of 60 to 80 beats per minute at
rest and 90 to 115 beats per minute during moderate exercise
is appropriate.
For the AFFIRM study, adequate control was defined as
an average heart rate of up to 80 bpm at rest and either
an average rate of up to 100 bpm over at least 18 hours of
ambulatory Holter monitoring with no rate greater than
100% of the maximum age-adjusted predicted exercise heart
rate, or a maximum heart rate of 110 bpm during a 6-minute
walk test [37].
The selection of appropriate rate-control therapy for
each patient should include consideration of the drug’s
potential impact on comorbid conditions such as hyperten-
sion, ischemic heart disease, and hypertrophic cardiomyopa-
thy [36].
Generally, beta-blockers and nondihydropyridine cal-
cium channel blockers are well tolerated; however, they are
not always effective at controlling heart rate [82].
Beta-blockers maybe especially useful in the presence of
high adrenergic tone or symptomatic myocardial ischemia
occurring in association with AF, but they should be used
with caution in patients with asthma [6, 59]. Amiodarone,
usually initiated for rhythm control, may continue to be used
inadvertently for rate control when patients have lapsed into
permanent AF [6, 13]. Long-term use of amiodarone may
result in end-organ toxicity (pulmonary, hepatic, thyroid,
neurologic, and skin) [83].
Digitalics are effective for control of heart rate at rest
but not during exercise. The patients should be monitored
for signs of digoxin toxicity, especially in those with reduced
renal function, advanced age, acute or chronic hypoxia, or
thyroid disease [6, 84].
Nondihydropyridine calcium channel antagonists should
be avoided in patients with systolic heart failure because of
their negative inotropic effect [6].
According to latest ESC guidelines, dronedarone is a first-
line drug for rhythm control in patient with AF, but it is not
currently approved for permanent AF to pharmacological
rate control [6].
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8. AntithromboticManagement
Unless contraindicated, chronic oral anticoagulation therapy
(OAC) is recommended in patients with a CHADS2 (cardiac
failure, hypertension, age, diabetes, and stroke (doubled))
score of ≥2 [6, 85] to achieve an international normalized
ratio (INR) between 2.0 and 3.0. In patients with a CHADS2
score of 0-1, or where a more detailed stroke risk assessment
is indicated, the latest guidelines recommend the use of the
CHA2DS2-VASc (congestive heart failure, hypertension, age
≥ 75 (doubled), diabetes, stroke (doubled), vascular disease,
age 65–74, and sex category (female)) score [86]. Indeed,
in patients with CHA2DS2-VASc ≥2 OAC is recommended
whereas with CHA2DS2-VASc = 1 either OAC or aspirin
75–325mg daily can be chosen although OAC should be
preferred. In case of CHA2DS2-VASc = 0, no antithrombotic
therapy is preferred although 75–325mg daily aspirin can be
administered depending on the physician’s choice.
Moreover, the new AF guidelines emphasize the impor-
tance of bleeding risk assessment before starting antico-
agulation. In this case, the HAS-BLE bleeding risk score
[87] is recommended (hypertension, abnormal renal and
liver function, stroke, bleeding, labile INRs, elderly (>65
years), drugs, or alcohol concomitantly). A score of ≥3 is
considered indicative of “high-risk” patients who require
caution and regular review after starting antithrombotic
therapy [6]. Multiple studies have demonstrated that oral
anticoagulation with warfarin is effective for prevention
of thromboembolism in AF patients [88–93], but it is
underused because of the risk of bleeding [94]. Dabigatran
etexilate is a new, effective, reversible, rapid-acting, oral
direct inhibitor of thrombin [95]. Dabigatran has been
shown to be at least as safe and effective as warfarin
therapy in RE-LY, a large-scale, international, multicenter
trial (randomized evaluation of long-term anticoagulant
therapy) [96]. Where oral anticoagulation is an appropriate
therapy, dabigatran may be considered as an alternative to
adjusted -dose vitamin K antagonist (VKA) therapy. If a
patient is at low risk of bleeding (e.g., HAS-BLED score of 0–
2), dabigatran 150mg b.i.d. may be considered in view of the
improved efficacy in the prevention of stroke and systemic
embolism (but lower rates of intracranial haemorrhage and
similar rates of major bleeding events, when compared with
warfarin).
When a patient has a measurable risk of bleeding (e.g.,
HAS-BLED score of ≥3), dabigatran etexilate 110mg b.i.d.
may be considered, in view of a similar efficacy in the
prevention of stroke and systemic embolism (but lower
rates of intracranial hemorrhage and of major bleeding
compared with VKA). In patients with CHA2DS2-VASc
score ≥2, dabigatran 110mg b.i.d. may be considered, in
view of a similar efficacy with VKA in the prevention of
stroke and systemic embolism but lower rates of intracranial
haemorrhage and major bleeding compared with the VKA
and aspirin [6].
In patients with no stroke risk factors (e.g., CHA2DS2-
VASc = 0), either aspirin 75–325mg daily or no anti-
thrombotic therapy is recommended. Where possible, no
antithrombotic therapy should be considered for such
patients, given the limited data on the benefits of aspirin in
this patient group (i.e., lone AF) and the potential for adverse
effects, especially bleeding [6].
The RE-LY [75] was reviewed by the 2011 Focused
Update Writing Group [7], but recommendations about its
use are not included in this focused update, because dabiga-
tran was not approved for clinical use by the FDA at the time
of organizational approval.
9. Conclusions
Although effective therapies have been identified in concrete
cases, a treatment modality offering efficacy in most cases
of AF remains to be established. It is essential to gain
further insight to the physiopathological mechanisms of AF
to develop drugs with improved efficacy and safety profiles
in the treatment of this widespread cardiac arrhythmia.
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